Company: HRTX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-060882
Chunk: 53

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 53
---
:----|:--------------------------------------------------------------------------------------------|-----------:|:----|---:|:----|:----------------------------------------------------------------------------|-----:|:----|---:|:----|:-------------------------------------------------------------------------------------------------------------------------------------------|-----------:|:----|---:|
| Equity compensation plans approved by security holders     |     |                                                                                             | 24,137,017 |     | -1 |     | $                                                                           | 4.96 |     | -2 |     |                                                                                                                                            | 13,045,966 |     | -3 |
| Equity compensation plans not approved by security holders |     |                                                                                             |  3,925,000 |     | -4 |     | $                                                                           | 1.47 |     | -5 |     |                                                                                                                                            |          - |     |    |
| Total                                                      |     |                                                                                             | 28,062,017 |     |    |     | $                                                                           | 4.46 |     |    |     |                                                                                                                                            | 13,045,966 |     |    |

(1) Consists of 22,331,501 options (assuming maximum achievement for performance-based options) and 1,805,516 restricted stock units outstanding under the 2007 Plan. (2) Does not reflect restricted stock units included in the first column because restricted stock units do not have an exercise price. (3) Consists of 12,125,013 shares of common stock available for future issuance under our 2007 Plan and 920,953 shares of common stock available for future issuance under the Employee Stock Purchase Plan. The number of shares that may be purchased under the current Employee Stock Purchase Plan purchase period is indeterminable because it is dependent on individual contributions as well as our stock price at the end of the purchase period. (4) Consists of 3,750,000 options (assuming maximum achievement for performance-based options) and 175,000 restricted stock units granted outside of the 2007 Plan as inducement equity awards. All such options were granted with an exercise price that equals fair market value of the underlying common stock on the grant dates and expire no later than 10 years from the date of grant. The options and restricted stock units have vesting schedules that generally provide for them to be fully vested four years after the date of grant. (5) Does not reflect restricted stock units included in the first column because restricted stock units do not have an exercise price.

39

Pay versus Performance

As required by Section 953(a